SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001520138-22-000201
Filing Date
2022-05-11
Accepted
2022-05-11 17:22:49
Documents
64
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR PERIOD ENDING MARCH 31, 2022 bivi-20220331_10q.htm   iXBRL 10-Q 767202
2 EXHIBIT 31.1 bivi-20220331_10qex31z1.htm EX-31.1 12091
3 EXHIBIT 31.2 bivi-20220331_10qex31z2.htm EX-31.2 12255
4 EXHIBIT 32.1 bivi-20220331_10qex32z1.htm EX-32.1 5277
5 EXHIBIT 32.2 bivi-20220331_10qex32z2.htm EX-32.2 5128
  Complete submission text file 0001520138-22-000201.txt   4044675

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bivi-20220331.xsd EX-101.SCH 39839
7 XBRL CALCULATION FILE bivi-20220331_cal.xml EX-101.CAL 38544
8 XBRL DEFINITION FILE bivi-20220331_def.xml EX-101.DEF 108501
9 XBRL LABEL FILE bivi-20220331_lab.xml EX-101.LAB 268132
10 XBRL PRESENTATION FILE bivi-20220331_pre.xml EX-101.PRE 216737
58 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20220331_10q_htm.xml XML 632295
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

IRS No.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39015 | Film No.: 22914792
SIC: 2834 Pharmaceutical Preparations